Nasdaq Biotech Firm Invests $212 Million in Decentralized Prediction Market Token

Enlivex Therapeutics, a Nasdaq-listed biotech company, is making a significant move into the crypto market with a $212 million investment. The firm will utilize this capital to purchase RAIN token, the utility token behind Rain decentralized prediction market on the Arbitrum network. This marks the first instance of a corporate strategy focusing specifically on a prediction market token.